SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer

Boisteau, Émeric; François, Ετιεννε; Aparicio, Thomas; Malicot, Karine Le; Boulahssass, Rabia; Lecomte, Thierry; Laurent–Puig, Pierre; Guiu, Boris; Paillaud, Éléna; Galais, Marie-Pierre; Ataz, Daniel Lopez-Trabada; Tougeron, David; Dourthe, Louis-Marie; Guimbaud, Rosine; Samalin, Emmanuelle; Moreau, Marie; Louvet, Christophe; Lepage, Côme; Lièvre, Astrid

doi:10.1016/j.dld.2022.03.001

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12] It has been recently reported that VEGFR2 inhibition could reduce tumor growth and vascularity for diffuse-type cancer, [13] and ramucirumab treatment has tremendous potential to improve the median overall survival. [14][15][16][17] In this regard, VEGFR2 inhibition is clinically accepted as an important therapeutic strategy for patients with HER2-negative tumors.…”

Section: Introductionmentioning

confidence: 99%

Bioprinted Organoids Platform with Tumor Vasculature for Implementing Precision Personalized Medicine Targeted Towards Gastric Cancer

Kim,

Gao

et al. 2023

Adv Funct Materials

View full text Add to dashboard Cite

Accurate prediction of treatment response for cancer patients is essential for overcoming intrinsic therapy resistance that results from genetic heterogeneity, varying tumor growth kinetics, and the complex tumor microenvironment. To achieve this goal, there is an urgent need for effective preclinical in vitro models that recapitulate the molecular–pathologic features and intricate ecology of native tumors for precision medicine. In this study, a vascularized organoid model (VOM) composed of patient‐derived gastric cancer organoids (PDOs), perfusable endothelium, and stomach decellularized extracellular matrix is presented that enables the prediction of clinical response to VEGFR2‐targeted therapy in gastric cancer patients. The results indicate that VOMs are dependent on the PDO molecular subtype. Moreover, VOMs accurately reproduce the clinically observed responses of patients treated with VEGFR2 inhibitor. Therefore, VOMs represent a valuable platform for providing clinical predictions for personalized testing and potential discovery of therapeutic drugs in various cancers that lack standardized regimens.

show abstract